Tumor Necrosis Factor-Alpha Inhibitor Use and Malignancy Risk: A Systematic Review and Patient Level Meta-Analysis

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2025 Feb 13

PMID 39941759

Authors

Conor B Driscoll

Jordan M Rich

Dylan Isaacson

Joseph Nicolas

Yu Jiang

Xinlei Mi

Christopher Yang

Victoria Kocsuta

Regine Goh

Niti Patel

Eric Li

Mohammad Rashid Siddiqui

Travis Meyers

John S Witte

Linda Kachuri

Hui Zhang

Molly Beestrum

Philip Silberman

Edward M Schaeffer

Shilajit D Kundu

Affiliations

Soon will be listed here.

Abstract

Over the last two decades, tumor necrosis factor-alpha inhibitors (TNF-Is) have become standard therapies for chronic inflammatory disorders, with an ongoing expansion of indications and off-label applications [...].

References

Urquhart L . Top companies and drugs by sales in 2021. Nat Rev Drug Discov. 2022; 21(4):251. DOI: 10.1038/d41573-022-00047-9. View

Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P . Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008; 59(9):1270-8. DOI: 10.1002/art.24001. View

Loftus Jr E, Colombel J, Schreiber S, Randall C, Regueiro M, Ali T . Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials. Clin Gastroenterol Hepatol. 2016; 14(12):1753-1762. DOI: 10.1016/j.cgh.2016.07.019. View

Weinblatt M, Fleischmann R, van Vollenhoven R, Emery P, Huizinga T, Cutolo M . Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population. Arthritis Res Ther. 2015; 17:325. PMC: 4644627. DOI: 10.1186/s13075-015-0841-9. View

Emery P, Fleischmann R, Doyle M, Strusberg I, Durez P, Nash P . Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function.... Arthritis Care Res (Hoboken). 2013; 65(11):1732-42. DOI: 10.1002/acr.22072. View

Mercer L, Galloway J, Lunt M, Davies R, Low A, Dixon W . Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2016; 76(3):497-503. PMC: 5446004. DOI: 10.1136/annrheumdis-2016-209389. View

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

Urquhart L . Top companies and drugs by sales in 2020. Nat Rev Drug Discov. 2021; 20(4):253. DOI: 10.1038/d41573-021-00050-6. View

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

10.

Koninckx P, Craessaerts M, Timmerman D, Cornillie F, Kennedy S . Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod. 2008; 23(9):2017-23. PMC: 2517154. DOI: 10.1093/humrep/den177. View

11.

Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z . Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2010; 62(4):917-28. DOI: 10.1002/art.27348. View

12.

Genovese M, Mease P, Thomson G, Kivitz A, Perdok R, Weinberg M . Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007; 34(5):1040-50. View

13.

Kimball A, Okun M, Williams D, Gottlieb A, Papp K, Zouboulis C . Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016; 375(5):422-34. DOI: 10.1056/NEJMoa1504370. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45(Pt A):139-45. PMC: 4639420. DOI: 10.1016/j.cct.2015.09.002. View

15.

Weisman M, Paulus H, Burch F, Kivitz A, Fierer J, Dunn M . A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford). 2007; 46(7):1122-5. DOI: 10.1093/rheumatology/kem033. View

16.

Wetzman A, Lukas C, Gaujoux-Viala C, Mamtani R, Barnetche T, Combe B . Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis. Arthritis Care Res (Hoboken). 2021; 75(2):260-271. DOI: 10.1002/acr.24784. View

17.

Calip G, Patel P, Adimadhyam S, Xing S, Wu Z, Sweiss K . Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. Int J Cancer. 2018; 143(5):1062-1071. PMC: 6103834. DOI: 10.1002/ijc.31407. View

18.

Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A . Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010; 62(8):2517-24. DOI: 10.1002/art.27511. View

19.

Goel N, Stephens S . Certolizumab pegol. MAbs. 2010; 2(2):137-47. PMC: 2840232. DOI: 10.4161/mabs.2.2.11271. View

20.

Wang J, Yin W, Zhou L, Zhou G, Liu K, Hu C . Risk of non-melanoma skin cancer for rheumatoid arthritis patients receiving TNF antagonist: a systematic review and meta-analysis. Clin Rheumatol. 2019; 39(3):769-778. DOI: 10.1007/s10067-019-04865-y. View